Back to top

Image: Bigstock

Amgen's Biosimilar of AbbVie's Humira to Face FDA Panel

Read MoreHide Full Article

Amgen Inc. (AMGN - Free Report) announced that the FDA’s Arthritis Advisory Committee will review data supporting the company's biologics license application for ABP 501, a biosimilar version of AbbVie Inc.’s (ABBV - Free Report) best-selling drug, Humira.

A final decision regarding the approval status of ABP 501 is expected by Sep 25, 2016. It is also under review in the EU.

Humira, an anti-TNF-α monoclonal antibody, is approved in many countries for the treatment of a wide range of inflammatory diseases. The drug recorded worldwide sales of $14 billion in 2015 and was one of the top-selling products in the U.S. in 2014.

Currently, Amgen has nine biosimilar candidates in its portfolio representing annual revenues of more than $3 billion. The company plans to launch its first biosimilar in 2017 followed by four others through 2019, subject to approval.

We note that Amgen itself is facing biosimilar competition in the U.S. Zarxio, the first FDA-approved biosimilar, was launched by Novartis AG’s (NVS - Free Report) generic arm, Sandoz, in Sep 2015. Zarxio is the biosimilar version of Amgen’s blockbuster drug, Neupogen. A couple of key drugs from Amgen’s portfolio – Neulasta and Enbrel – could also start facing biosimilar competition soon.

Notably, Sandoz’s biosimilar version of Enbrel is expected to come up before the FDA’s Arthritis Advisory Committee next month.

Considering that the market for biosimilars is highly lucrative, competition in this space is intensifying with pharmaceutical and biotech companies racing to develop the same.

Amgen is a Zacks Rank #3 (Hold) stock. Bristol-Myers Squibb Company (BMY - Free Report) is a better-ranked stock in the health care sector, carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Novartis AG (NVS) - free report >>

Bristol Myers Squibb Company (BMY) - free report >>

Amgen Inc. (AMGN) - free report >>

AbbVie Inc. (ABBV) - free report >>

Published in